Welcome to Last Minute Lecture.
This free chapter overview is designed to help students review and understand key concepts.
These summaries supplement not replaced the original textbook and may not be redistributed or resold.
For complete coverage, always consult the official text.
Welcome to the Deep Dive.
Today, we're really going to focus in, skip the basics, and pull up the essential pharmacology knowledge for anxiety disorders, specifically for advanced practice.
Exactly.
We're sifting through the latest clinical guidance on GAD panic disorder, SAD.
The goal here is the practical stuff, mechanisms, treatment approaches, and those key clinical pearls you need day to day.
And we have to start by acknowledging just how common these are.
I mean, anxiety disorders are the biggest group of psychiatric disorders out there, affecting what, over 30 million Americans?
That's right.
And here's a really important note from the source material, something maybe counterintuitive.
GAD prevalence actually goes up with age.
It's the most frequent psychiatric issue in the elderly.
Which correctly ties into how tricky diagnosis can be, right?
Oh, definitely.
Patients often don't come in saying, I'm worried all the time.
They present with, you know, physical symptoms, headaches, stomach problems, just feeling generally unwell.
Vague somatic complaints, the textbook calls them.
Exactly.
The worry gets buried.
So understanding the underlying neurobiology is crucial to connect those physical symptoms back the anxiety itself.
Okay.
So if the patient presentation is often this chronic tension and
hypervigilance, what's going wrong underneath?
What are we targeting with meds?
So the core idea is dysregulation in the brain's fear circuitry.
You've got these neurodrenergic systems that seem to have, well, too low a threshold for firing up.
Kind of on a hair trigger.
Sort of, yeah.
And then GABA, which is our main brake pedal in the CNS, the primary inhibitory system, isn't quite doing its job effectively enough.
So that classic fight or flight response, the adrenaline, the norepinephrine, cortisol surge, heart racing, breathing faster, it's kicking in inappropriately.
Precisely.
It's happening in response to maybe an internal worry or an imagined threat, not an actual lion chasing you.
So our pharmacologic targets are really those three key players, the norepinephrine or NE, serotonin, 5 -HT, and GABA.
Got it.
But before we even think about messing with those neurotransmitters, the sources are really clear.
You have to rule out other causes first.
Absolutely critical.
A thorough medical workup is non -negotiable.
Things like hyperthyroidism, B12 deficiency, even heart problems can look a lot like anxiety.
And don't forget substances.
Caffeine is a big one, obviously, but also cannabis, amphetamines, even some prescription drugs like certain bronchodilators.
Right.
Check everything.
Only after you've ruled out those mimics can you really apply the diagnostic criteria for, say, GAD.
Which, just quickly, involves that excessive worry for at least six months, trouble controlling it, and three or more of those physical symptoms like restlessness, fatigue, muscle tension, irritability, concentration issues, sleep problems.
Yeah, those core physiological arousal symptoms.
And once you have the diagnosis, treatment usually involves more Right.
It's typically multimodal.
CDT, cognitive behavioral therapy, is still considered the top psychotherapy approach for GAD.
Definitely.
But focusing on the pharmacotherapy side, what are we actually aiming for?
It's not just making people feel a little better.
No.
The goal is remission.
Complete resolution of symptoms, getting the patient back to their normal level of functioning.
Anything less than that.
Well, it carries risk.
A big risk.
The data way up to around 45 % for GAD patients.
That's huge.
So persistence is key, both from us and the patient.
Absolutely.
And that applies to the treatment timeline too.
We usually start low, go slow, and assess response around, what, four to eight weeks?
Yeah.
Though I've seen some discussion, especially with SNRIs and prominent physical symptoms, maybe waiting even 12 weeks before calling it a failure.
Is eight weeks sometimes too quick?
It potentially can be.
But the crucial takeaway here is even if symptoms do resolve by week eight or week 12, you don't stop there.
Treatment needs to continue for a full 12 months after remission.
A full year.
Wow.
Yeah.
To really lock in that remission and minimize the chance of relapse.
Patient education on this timeline is absolutely vital.
They need to know it's a longer term commitment.
Okay.
Let's dive into the first line agents then.
We're talking SSRIs and SNRIs.
We know their first line.
So let's focus on clinical nuances.
Okay.
With SSRIs, the big challenge, as you know, is that delay in onset.
You've got sertraline, acetylopram, good evidence, better than placebo for GAD.
But it takes time.
Two to four weeks usually for the main effect.
You really have to prep the patient for that way.
Although wasn't there a note about proxetine maybe showing some effect a bit sooner, like week one?
Yeah.
Sometimes you see a little mood improvement earlier with proxetine, but the full anxiolytic effect still takes time.
And we absolutely have to talk about side effects because that's where adherence often falls apart.
Sexual dysfunction is a big one, right?
Yeah.
Decreased libido, anergasmia.
Very common and it's often dose related.
Also that initial jitteriness or agitation some patients get, you have to warn them it often subsides.
And the critical warning.
Yeah.
Never ever combine an SSRI with an MAO inhibitor.
That's the setup for potentially fatal serotonin syndrome.
Non -negotiable contraindication.
Okay.
Moving over to SNRIs.
These add the norepinephrine reuptake inhibition to the serotonin piece.
So a dual mechanism.
Right.
Venlafaxine XR is a common go -to, often up to 225 milligrams a day.
It seems particularly good for patients who also have depression or significant somatic procomplaints alongside the anxiety.
And deloxetine.
Deloxetine is noted for having maybe a more balanced effect on both serotonin and norepinephrine.
And it also seems quite helpful for those physical pain symptoms that can mask or accompany anxiety.
But the key difference, the monitoring requirement for SNRIs versus SSRIs is blood pressure, isn't it?
Especially with venlafaxine.
Correct.
There's a documented risk of clinically significant increases in blood pressure, particularly with venlafaxine.
So that needs regular monitoring.
Okay.
Now let's shift gears to the benzodiazepines,
they work fast, they work well for acute symptoms, but they come with some serious baggage.
Absolutely.
They're sedative hypnotics, fantastic for getting acute anxiety under control quickly, maybe bridging those first few weeks while the antidepressant kicks in, but they're really for short -term use.
They hit those somatic symptoms hard and fast.
Yeah.
But the key limitation the techs point out is they don't really touch the underlying worry component of Gady much.
Exactly.
They calm the physical storm, but not the cognitive one.
They work by binding to GABA receptors, basically making GABA work better, enhancing that inhibitory effect by letting more chloride ions into the neuron.
Hyperpolarizing it.
Right.
Now when you're choosing a BZD, the pharmacokinetics matter a lot.
You've got high potency ones like alprazolam, clonuspam, lorazepam.
But for certain populations, like the elderly or those with liver issues, there's a metabolic pathway we need to remember, right?
Yes.
The LOT drugs, lorazepam, oxazepam, and sometimes tamazepam is included.
These are metabolized mainly through glucuronidation, a simpler one -step process outside the main CYP450 liver enzyme system.
Which means less risk of the drug building up and causing excessive sedation in patients with slower metabolism or liver impairment.
Exactly.
They're generally considered safer in those groups, but regardless of which BZD you use, long -term use, we're talking more than several weeks, brings the risk of tolerance and dependence.
Collerance to the sedative effects especially.
And then dependence, which makes stopping them tricky.
We need to talk about withdrawal.
Yeah.
And it's important to differentiate what happens when someone stops.
The book outlines three possibilities.
Okay, let's break that down.
If the original anxiety symptoms just come back to where they were before treatment, that's - That's relapse.
Straightforward return of the underlying condition.
Okay.
But what if the symptoms come back worse than they were initially?
That's rebound.
It's a sign the body had adapted to the drug and it indicates the taper is likely too fast.
And then there's the really serious one, true withdrawal.
Right.
This involves new symptoms that weren't part of the original anxiety picture.
Things like psychosis, confusion, or even seizures in severe cases.
Abrupt discontinuation is dangerous, period.
Which is why the taper has to be slow and careful.
The general rule is - At least four weeks long, sometimes much longer depending on the duration and dose.
You typically aim for about a 10 % dose reduction every say three to four days, maybe even slower towards the end.
Very gradual.
And if the worst happens, an overdose.
The antidote is flumazenil.
It's a competitive antagonist at the BZD receptor site.
But it has a really short half -life, only about an hour or so.
Meaning the sedation can come back after the flumazenil wears off.
Exactly.
You often need repeated doses and you have to monitor very closely, partly because flumazenil itself can potentially lower the seizure threshold, especially in someone physically dependent on BZDs.
Okay.
Let's pivot to second line treatments.
If SSRIs or SNRIs don't work or aren't tolerated, where does something like buspirone fit in?
Buspirone is interesting.
It's a partial agonist at serotonin 1A receptors.
Its efficacy is maybe slightly less robust than BZDs for pure anxiety symptoms, but it's considered a solid second line option or an add -on therapy for GAD.
And it's big advantages.
It's side effect profile and lack of dependence potential.
It doesn't have those hypnotic muscle relaxant or anticonvulsant effects you see with BZDs.
And crucially, there's minimal risk of abuse or dependence.
Which makes it a go -to, or at least a preferred agent, if your patient has any history of alcohol or substance abuse problems.
Absolutely.
That's a key clinical pearl.
The main drawback, though, is similar to the antidepressants.
Takes two to three weeks, sometimes longer, to see the real benefit.
So again, patient education is key for compliance.
They need to stick with it.
All right.
Now, third line.
The text mentions imipramine, a triceclic antidepressant, as having evidence for GAD and panic disorder.
But TCAs, they feel kind of old school now, and they are risky.
They definitely work, but they come with a heavy side effect burden.
You've got all the anticholinergic effects, dry mouth, blurred vision, constipation, and urinary hesitancy.
Annoying, but usually manageable.
The real worry is overdose, isn't it?
That's the major concern.
TCAs are profoundly toxic in overdose.
They can cause life -threatening ventricular arrhythmias and seizures.
And they're strictly contraindicated in patients with narrow angle glaucoma or certain heart conduction problems.
Correct.
So their use is pretty limited these days, especially in primary care settings.
Definitely not a first or even second choice for most.
Okay.
And just briefly, other adjunctive agents.
Pregabalin gets a mention.
Yeah.
Pregabalin isn't FDA approved specifically for anxiety in the U .S., but studies have shown it can be effective, maybe comparable to lorazepam, especially for the physical symptoms of anxiety.
And atypical antipsychotics.
Generally reserved for really treatment -resistant cases, usually as an add -on therapy, because their metabolic side effects, weight gain, diabetes risk, lipid changes are significant concerns.
Let's touch on a couple of special populations, geriatric patients.
Right.
We mentioned the L -O -T -B -Z -Ds, lorazepam, oxazepam, being preferred due to metabolism.
But the broader principle is start low, go slow with all psychotropics and older adults, because their metabolism and excretion are generally slower.
Makes sense.
And pregnancy.
Always a complex discussion.
Very complex.
You're balancing the risks of untreated maternal anxiety or depression, which can include miscarriage, preeclampsia, poor self -care against potential fetal risks from medication exposure.
And the categories.
Most antidepressants are category C.
Proxetine is D, bupropion is B.
Correct.
And there have been some meta -analyses linking specific SSRIs, notably fluoxetine and proxetine, to slightly increased risks of certain birth defects, like specific heart defects or
craniosynostosis, though the absolute risk increase is small and debated.
It requires a very careful individualized discussion with the patient.
Definitely a conversation to have early and often if pregnancy is planned or occurs.
One last pearl.
Managing that common SSRI side effect, sexual dysfunction.
Yeah, you can't just ignore it, because patients will stop their meds.
The strategies include trying to lower the dose, maybe adding another medication like sildenafil for men, or switching to an antidepressant less likely to cause it, like bupropion or mirtazapine.
Okay, great.
So to quickly wrap up the treatment hierarchy for GAD.
First line is generally an SSRI or SNRI.
Right.
Give it an adequate trial.
If that fails or isn't tolerated, you move to second line options like buspirone or maybe carefully consider imiprimin, weighing those risks.
And if you've had two adequate trials of first or second line agents fail, then you start thinking about adjunctive therapies or referral.
Exactly.
And throughout that whole process, the biggest thing we can probably improve is patient education, especially hammering home that delayed onset for SSRIs, SNRIs, and buspirone.
So patients don't give up too early.
Precisely.
And educating them about the need for that long -term 12 -month minimum treatment course after remission to really prevent relapse, it takes persistence.
That seems to be the consistent message from the sources.
Which kind of leads to a final thought to leave our listeners with.
Given the known severe overdose toxicity of TCAs like imirpamon and the fact that we now have potentially safer evidence -supported alternatives emerging, even if some are off -label like pregabalin,
is it time for clinical guidelines, particularly for primary care, to more formally push TCAs further down the list or even actively discourage their use for anxiety purely from a safety standpoint?
That's a really important question to consider for future practice.
How much risk are we willing to accept when other options exist?
Something to definitely mull over.
Okay, that brings us to the end of this deep dive.
Thanks for joining us.
From the Last Minute Lecture Team, we hope this helped solidify your understanding of anxiety pharmacotherapy.
Thanks, everyone.